SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial
Year: 2026
Type: article
Source: The Lancet Oncology
Authors: Giulio Francolini, Vanessa Di Cataldo, Saverio Caini, Pietro Garlatti, Michele Aquilano, Niccolò Bertini, Alessio Bruni, Gianluca Ingrosso, Rolando M D'Angelillo, Luca Tagliaferri, Barbara A Jereczek-Fossa, Matteo Augugliaro, Luca Triggiani, Silvana Parisi, Lorenzo Masieri, Riccardo Campi, Richard K Valicenti, Gabriele Simontacchi, Daniela Greto, Pierluigi Bonomo, Mauro Loi, Chad Tang, Lorenzo Livi, Giulia Marvaso, Filippo Alongi, Andrea Gaetano Allegra, Andrea Lancia, Fabio Arcidiacono, Annamaria Vinciguerra, Ciro Franzese, Giorgia Timon, Cinzia Iotti, Monica Mangoni, Isacco Desideri, Icro Meattini, Carlotta Becherini, Raffaela Doro, Laura Masi
Institutions: Azienda Ospedaliero-Universitaria Careggi, University of Modena and Reggio Emilia, University of Perugia, University of Rome Tor Vergata, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, University of Milan, European Institute of Oncology, Azienda Sanitaria Unità Locale di Reggio Emilia, University of Brescia, University of Messina, University of Florence, University of California, Davis, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7166551511